Sarepta Therapeutics, INC 8-K filings

Sarepta Therapeutics reported Q2 2026 results with $328.7 million in net product revenue and achieved both GAAP and non-GAAP operating profitability, while narrowing full-year revenue guidance.

Sarepta Therapeutics announces the appointment of Michael Severino, M.D. as Chief Executive Officer, succeeding Douglas Ingram, who will transition to a consulting role.

Sarepta Therapeutics stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan at the annual meeting.

Sarepta Therapeutics reported Q1 2026 financial results, with total revenues of $730.8 million, driven by strong PMO net revenues and advancements in its siRNA pipeline.

Sarepta Therapeutics, Inc. announced that CEO Douglas Ingram will retire by the end of 2026 or upon the appointment of his successor.

Sarepta Therapeutics announced its fourth quarter and full-year 2025 financial results, highlighting significant revenue growth for the year, strategic debt refinancing, and positive clinical advancements for its Duchenne muscular dystrophy therapies.

Sarepta Therapeutics announced preliminary Q4 and full-year 2025 net product revenues, exceeding its ELEVIDYS sales floor and reporting a strong cash position.

Sarepta Therapeutics exchanges $291.4 million of 2027 convertible notes for new 2030 notes with a higher interest rate and a cash payment.

Sarepta Therapeutics announced a private exchange of $291.4 million of its 2027 convertible notes for new 2030 notes with a higher interest rate and a cash payment.

Sarepta Therapeutics' CEO, Douglas S. Ingram, was granted $12 million in equity awards, split between time-based RSUs and performance-based awards tied to Incentive EBITDA.

Sarepta Therapeutics reported Q3 2025 financial results, including a revenue decline and the ESSENCE confirmatory study for PMO therapies not achieving its primary endpoint, though showing positive trends.

Sarepta Therapeutics exchanged $700 million of existing convertible notes for new 4.875% convertible notes due 2030, common stock, and cash, alongside a private placement of additional common stock.

Sarepta Therapeutics announced a privately negotiated exchange of $700 million in convertible notes and a $20 million private placement of common stock.

Sarepta Therapeutics announced the departure of its Chief Technical Operations Officer, Bilal Arif, as part of a strategic restructuring and pipeline prioritization.

Sarepta Therapeutics announced that the U.S. Food and Drug Administration has placed a clinical hold on its investigational gene therapy clinical trials for limb girdle muscular dystrophy and revoked its AAVrh74 platform technology designation.

Sarepta Therapeutics is undertaking a significant strategic restructuring, including a 36% workforce reduction and pipeline reprioritization, while providing an update on its ELEVIDYS gene therapy label and reporting preliminary Q2 2025 financial results.

Sarepta Therapeutics, Inc. announced that its stockholders approved amendments to its 2018 Equity Incentive Plan and 2013 Employee Stock Purchase Plan, increasing authorized shares for equity awards and employee purchases, alongside the re-election of directors and executive compensation.

Sarepta Therapeutics announces a successful 2024, marked by significant revenue growth and strategic pipeline expansion, driven by the successful launch of ELEVIDYS and key collaborations.

Sarepta Therapeutics has entered into a five-year, $600 million senior secured revolving credit agreement to bolster its financial flexibility.

Sarepta Therapeutics announced preliminary unaudited full-year 2024 net product revenue of $1.79 billion, exceeding guidance by over $100 million, and a cash position of approximately $1.5 billion.

Sarepta Therapeutics has entered into an exclusive licensing and collaboration agreement with Arrowhead Pharmaceuticals, acquiring rights to multiple clinical and pre-clinical programs, and investing $325 million in Arrowhead stock.

Sarepta Therapeutics has appointed Deirdre Connelly to its board of directors and increased the maximum number of board members to nine.

Sarepta Therapeutics has increased the number of shares available under its 2024 Employment Commencement Incentive Plan and held its annual meeting of stockholders.